Phase II study of campath-1H in patients with lymphoplasmacytic lymphoma (Waldenstrom's macroglobulinemia)

Trial Profile

Phase II study of campath-1H in patients with lymphoplasmacytic lymphoma (Waldenstrom's macroglobulinemia)

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 07 Jan 2013

At a glance

  • Drugs Alemtuzumab (Primary)
  • Indications Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jan 2013 Status changed from completed to withdrawn prior to recruitment as reported by ClinicalTrials.gov. (NCT00081068)
    • 07 Jan 2013 Status changed from completed to withdrawn prior to recruitment as reported by ClinicalTrials.gov. (NCT00081068)
    • 22 Oct 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top